Moreover, AF is a commonly reported adverse effect of mirabegron in clinical trials [74,75,76]; therefore, exploring the role of β3-AR in the pathophysiology of AF is of considerable interest. This evidence concerns the gene ADRB3 and atrial fibrillation.